Compare ARK Genomic Revolution ETF (ARKG) vs Stryker Corporation (SYK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Stryker Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Stryker Corporation trades at $328.17 (market cap $126.42B). The key difference: Stryker Corporation pays a 1.07% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | SYK | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $403.53 |
52-Week Low | $23.09 | $282.58 |
Market Cap | — | $126.42B |
Enterprise Value | — | $138.18B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Stryker (SYK) trades at $329.78, up 0.82% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 63.83% gross profit margin and consistent earnings beats in recent quarters, despite a Q1 2026 miss attributed to a temporary cyber disruption. Recent news highlights the company's innovation and market position as a medtech leader.
The outlook remains positive with a consensus price target of $388.44, representing ~18% upside. Key risks include execution challenges post-cyber incident and competitive pressures, but strong cash flow and dividend growth support long-term value. Investor sentiment is buoyed by unchanged full-year guidance and healthy end-market demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
